In this article, we will address the topic of Lodenafil from a broad and multidisciplinary perspective. Lodenafil is a topic of great relevance today, which has captured the attention of specialists and the general public. Throughout history, Lodenafil has played a fundamental role in various aspects of society, culture and everyday life. Through this article, we will explore the various approaches, debates and perspectives that revolve around Lodenafil, with the aim of offering a comprehensive and enriching vision on this topic.
![]() | |
Clinical data | |
---|---|
Trade names | Helleva |
Pregnancy category |
|
Routes of administration | By mouth |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H32N6O5S |
Molar mass | 504.61 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Lodenafil (also known as hydroxyhomosildenafil, trade name Helleva) is a drug belonging to a class of drugs called PDE5 inhibitor, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. Like udenafil and avanafil it belongs to a new generation of PDE5 inhibitors.
Lodenafil is formulated as a prodrug in the form of the carbonate ester dimer, lodenafil carbonate, which breaks down in the body to form two molecules of the active drug lodenafil. This formulation has higher oral bioavailability than the parent drug.[1]
It is manufactured by Cristália Produtos Químicos e Farmacêuticos in Brazil and sold there under the brand-name Helleva.[2]
It has undergone Phase III clinical trials,[3][4] but is not yet approved for use in the United States by the U.S. Food and Drug Administration.